Published in Arch Immunol Ther Exp (Warsz) on January 01, 1971
Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol. Endocrinology (1977) 1.09
Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland. Neoplasma (2006) 0.85
Estrogen and progesterone receptor status in breast cancer in Kuwait female population. Neoplasma (1993) 0.84
A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue. Neoplasma (2005) 0.81
Relations between epidermal growth factor receptor and oestrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients in Kuwait. Eur J Cancer (1992) 0.79
The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives. Eur J Gynaecol Oncol (2004) 0.79
Estrogen and progestin receptor levels in uterine leiomyomata: relation to the tumour histology and the phase of menstrual cycle. Eur J Gynaecol Oncol (1990) 0.79
Estrogen receptor in human breast cancer in relation to tumor morphology and endocrine therapy. Tumori (1978) 0.78
Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium. Eur J Gynaecol Oncol (1990) 0.77
Epidermal growth factor receptor and estrogen and progesterone receptors in breast cancers of premenopausal and postmenopausal patients. Tumori (1994) 0.77
[Steroid hormone receptors; their appearance in breast cancer; usefulness of the findings in the selection of patients for endocrine therapy and prognosis of tumor development]. Pol Tyg Lek (1984) 0.75
[Comparison of the accuracy of determination of blood serum concentrations of chorionic gonadotropins in pregnancy by the radioligand assay and radioimmunoassay]. Ginekol Pol (1980) 0.75
[Changes in contents of pituitary gonadotropins in castrated rats following implantation of ovaries into the kidneys]. Endokrynol Pol (1971) 0.75
[Human gonadotropins. I. Selected problems from the field of biologic methods in detection of gonadotropins]. Postepy Hig Med Dosw (1971) 0.75
[Human gonadotropins. II. Synthesis, concentration and isolation of LH activity from FSH activity]. Postepy Hig Med Dosw (1972) 0.75
[Diurnal rhythm of prolactin secretion in patients with type I diabetes mellitus]. Pol Tyg Lek (1982) 0.75
[An attempt to eliminate a high luteinizing hormone content from pituitary gonadotropin preparation of human menopausal urine origin and a further study of chorionic concentration]. Endokrynol Pol (1970) 0.75
[Changes in the estrogen receptor content in the growing uterus of an immature rat after gonadotropin (PMSG, HCG) or estrogen injection]. Endokrynol Pol (1982) 0.75
[Prolactin in the polycystic ovary syndrome (Stein-Leventhal syndrome)]. Ginekol Pol (1983) 0.75
[Determining estrogen receptors in neoplastic and normal human tissues: comparison of immunoenzyme and radioligand methods]. Nowotwory (1989) 0.75
Neutralization of LH and FSH activity in gonadotropin preparations (HMG) by means of anti-HCG immune serum. Arch Immunol Ther Exp (Warsz) (1971) 0.75
[Evaluation of the growing activity of human growth hormone]. Endokrynol Pol (1967) 0.75
[Prolactin secretion in patients with diabetes mellitus - TRH or bromocriptine function tests]. Endokrynol Pol (1982) 0.75
Comparison of luteinizing hormone and human chorionic gonadotrophin determinations by biological, radioreceptor and radioimmunoassay methods. Endokrynol Pol (1981) 0.75
[Hormones and breast neoplasms]. Nowotwory (1979) 0.75
[Pathogenesis of thyroid regeneration in women following strumectomy]. Pol Tyg Lek (1982) 0.75
[Stages of morphological differentiation of breast cancer and levels of estrogen and progestagen receptors]. Nowotwory (1988) 0.75
[Morphological structure of uterine myomas and levels of estrogen and progestagen receptors]. Nowotwory (1988) 0.75
[Occurrence of 4S and 8S forms of estrogen and progestin receptors in the cytosol of breast cancer in women]. Nowotwory (1983) 0.75
[Hormones and breast neoplasms]. Nowotwory (1978) 0.75
[Effect of sex hormones on the content of prolactin receptor in the liver of female rats]. Endokrynol Pol (1980) 0.75
[Amenorrhea-galactorrhea and hyperprolactinemia as indicators of the presence of pituitary adenoma - prolactinoma]. Pol Tyg Lek (1983) 0.75
[Levels of estrogen and progestagen receptors in uterine myomas in women during the menstrual cycle]. Nowotwory (1988) 0.75
[Hyperprolactinemia and galactorrhea in women after head injuries]. Pol Tyg Lek (1981) 0.75
[Evaluation of tamoxifen in the treatment of female patients with advanced breast cancer]. Nowotwory (1986) 0.75
[Serum prolactin level in women with hypothyroidism after menopause]. Pol Tyg Lek (1987) 0.75
[Condensation of gonadotropins from the urine of postmenopausal women]. Endokrynol Pol (1969) 0.75
Effect of median raphe nucleus electrocoagulation and serotonin synthesis blockade on oestrogen receptor content of rat uterus. Acta Physiol Pol (1983) 0.75
Changes in the concentrations of receptors of insulin-like growth factor-I, epithelial growth factor, oestrogens and progestagens in adenomyosis foci, endometrium and myometrium of women during menstrual cycle. Eur J Gynaecol Oncol (1998) 0.75
[Nuclear estrogen receptors in women with breast cancer]. Nowotwory (1988) 0.75
Purification of pituitary gonadotropins from the urine of women after menopause and trials of separating luteinizing from follicle stimulating hormone. Arch Immunol Ther Exp (Warsz) (1969) 0.75
Isolation of lymphocyte growth factor from the seeds of the kidney bean. Arch Immunol Ther Exp (Warsz) (1968) 0.75
[Prolactin levels and indicators of breast cancer risk in women with mastopathy]. Nowotwory (1982) 0.75
[Levels of estrogen and progestagen receptors in the endometrium and myometrium of women during the menstrual cycle]. Nowotwory (1988) 0.75
Studies on the application of the hormone-receptor reaction for determination of HCG or LH in human serum and urine. Endokrynol Pol (1981) 0.75
Quality control program of steroid receptor assays: an international study. Neoplasma (1992) 0.75
[Immunocytochemical evaluation of estrogen receptors in histological specimens of primary breast cancer]. Patol Pol (1990) 0.75
The influence of LH on synthesis of RNA, DNA, proteins and lipids and content of ascorbic acid and cholesterol in the luteinized rat ovary. Arch Immunol Ther Exp (Warsz) (1972) 0.75
[Estradiol binding in normal and neoplastic tissue]. Nowotwory (1973) 0.75
[Detection of specific prolactin binding sites in cell membranes of the rat liver]. Endokrynol Pol (1981) 0.75
[Amenorrhea-galactorrhea syndrome: clinical characteristics, prolactin secretion and estrogenic activity]. Ginekol Pol (1983) 0.75
[Isolation of gonadotrophins from human pituitary gland]. Endokrynol Pol (1966) 0.75
[The functional state of the pituitary-adrenal system in carcinoma of the cervix]. Endokrynol Pol (1972) 0.75
[Relationship between the effects of endocrinological treatment of breast cancer and the presence of estrogen receptor in the cancer tissue]. Nowotwory (1980) 0.75
[Estrogen activity and prolactin secretion in menopausal women at high risk of developing breast cancer]. Nowotwory (1984) 0.75
[Isolation of chorionic gonadotrophins from the urine of pregnant women]. Endokrynol Pol (1966) 0.75
The effect of actinomycin D on nucleic acid, protein, and lipid synthesis and contents of ascorbic acid and cholesterol influenced by LH in the luteinized rat ovary. Arch Immunol Ther Exp (Warsz) (1973) 0.75
Estimation of high affinity estradiol binding sites in the human breast cancer. Arch Geschwulstforsch (1975) 0.75